No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 77,712 | 78,618 | 81,120 | 84,947 | 84,104 | 87,630 | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 1,147 | 298 | -1,257 | 3,394 | 2,729 | 3,101 | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Oenon Holdings, Inc., established in 1920 and headquartered in Tokyo, Japan, operates as a diversified enterprise. The company's business foundation lies in biotechnologies derived from fermentation, enabling it to engage in a broad range of sectors. Its primary activities encompass the development and production of alcoholic beverages, various food products, specialized enzymes, and pharmaceuticals, alongside interests in real estate and other ventures. The alcoholic beverage division offers an extensive selection, including traditional Japanese shochu, sake, and umeshu plum wine, alongside chu-hi, processed liquors, and diverse wines. It also supplies brewing and industrial alcohol, as well as a variety of seasonings. For industrial and food applications, Oenon manufactures and markets numerous enzymes. These include lactase (a lactose hydrolytic enzyme), cellulase (for dietary fiber processing), glucose isomelase (used in fructose corn syrup production), protease (a proteolytic enzyme), dispase (for cell dispersion), and isoamylase (for starch processing). In the pharmaceutical segment, the company provides active pharmaceutical ingredients such as Pravastatin, utilized for managing hyperlipidemia, and Voglibose, for diabetes mellitus treatment. This division further produces starch for food processing, diagnostic medical products, and health-focused dietary supplements. Beyond these areas, Oenon Holdings engages in the sale and leasing of real estate properties. Its comprehensive operations also include transportation, cargo handling, and sundry other business activities, completing its multifaceted portfolio.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Oenon Holdings, Inc. (2533.T)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Oenon Holdings, Inc., established in 1920 and headquartered in Tokyo, Japan, operates as a diversified enterprise. The company's business foundation lies in biotechnologies derived from fermentation, enabling it to engage in a broad range of sectors. Its primary activities encompass the development and production of alcoholic beverages, various food products, specialized enzymes, and pharmaceuticals, alongside interests in real estate and other ventures. The alcoholic beverage division offers an extensive selection, including traditional Japanese shochu, sake, and umeshu plum wine, alongside chu-hi, processed liquors, and diverse wines. It also supplies brewing and industrial alcohol, as well as a variety of seasonings. For industrial and food applications, Oenon manufactures and markets numerous enzymes. These include lactase (a lactose hydrolytic enzyme), cellulase (for dietary fiber processing), glucose isomelase (used in fructose corn syrup production), protease (a proteolytic enzyme), dispase (for cell dispersion), and isoamylase (for starch processing). In the pharmaceutical segment, the company provides active pharmaceutical ingredients such as Pravastatin, utilized for managing hyperlipidemia, and Voglibose, for diabetes mellitus treatment. This division further produces starch for food processing, diagnostic medical products, and health-focused dietary supplements. Beyond these areas, Oenon Holdings engages in the sale and leasing of real estate properties. Its comprehensive operations also include transportation, cargo handling, and sundry other business activities, completing its multifaceted portfolio.
